Welcome to our dedicated page for Genenta Science S.p.A. American Depositary Shares news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science S.p.A. American Depositary Shares stock.
Genenta Science S.p.A. (symbol: GNTA) is a cutting-edge biotechnology company specializing in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and various types of cancer. The company leverages an innovative gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to target interferon-α expression specifically to tumor-infiltrating monocytes/macrophages. Utilizing a genetically modified, HIV-derived lentiviral vector, Genenta delivers the therapeutic gene into HSPCs, enabling these cells to selectively express interferon within the tumor microenvironment, thereby minimizing systemic toxicity.
One of Genenta's flagship products, Temferon, is designed to treat glioblastoma multiforme, a highly aggressive brain tumor. Another key product focuses on TIE2-expressing monocytes (TEMs), which are engineered to attack solid tumors using an innovative combination of transcriptional and microRNA-mediated control mechanisms.
In recent developments, Genenta Science has expanded its research to include refractory advanced genitourinary malignancies, such as renal cell cancer, as a second indication. The company's latest news highlights preliminary data from its ongoing Phase 1/2 clinical trials, demonstrating promising results in the dose-ranging stage.
With its headquarters in Milan, Italy, and extensive clinical operations in New York, Genenta Science is at the forefront of immuno-oncology, aiming to harness the body's own immune system to combat cancer effectively and safely. The company remains committed to advancing its pipeline and achieving breakthroughs in cancer treatment.
- Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication.
- Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial.
Bowling Green Bull (BGB) is a new initiative launched to connect Italian companies and entrepreneurs seeking growth in the U.S. financial markets. Supported by the American Chamber of Commerce in Italy and Genenta Science (Nasdaq: GNTA), BGB aims to facilitate interactions between listed and aspiring listed companies, banks, and advisors. The inaugural event is scheduled for autumn 2022, focusing on providing insights and guidelines for Italian firms navigating U.S. market entry.
Genenta Science (NASDAQ: GNTA) announced its participation in several scientific congresses in May and June 2022, showcasing advancements in immuno-gene therapy for cancer. Presentations include:
- ASGCT Annual Meeting: May 19 - TEM-GBM study findings.
- Brain Tumor Meeting: May 19-20 - Patient case using Temferon™.
- ASCO Annual Meeting: June 5 - Tumor immune microenvironment research.
- EHA Virtual Congress: June 10 - Gene-modified cells' effects.
Genenta focuses on innovative therapies targeting solid tumors to enhance immune responses.
Genenta Science (NASDAQ: GNTA) has appointed Tim Obara as Vice President of Business Development. Obara, who previously held senior roles at organizations such as AstraZeneca and GSK, is expected to enhance Genenta's commercial and R&D opportunities, particularly for its Temferon™ treatment. This therapy, currently in a phase 1/2a trial for glioblastoma multiforme patients, employs innovative gene therapy strategies. CEO Pierluigi Paracchi expressed optimism about Obara's experience aiding in the company's growth in solid tumor markets.
Genenta Science (NASDAQ: GNTA) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2021, with the SEC on May 2, 2022. The report is available on the company's investor relations website and the SEC's website. Genenta is specializing in hematopoietic stem cell gene therapy, particularly its Temferon™ treatment for Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter. The company emphasizes that forward-looking statements in the report are subject to risks and uncertainties, including those related to ongoing clinical trials.
Genenta Science (NASDAQ: GNTA) has announced an escalation in its ongoing Phase 1/2a clinical trial of Temferon™ for glioblastoma multiforme patients with an unmethylated MGMT gene promoter. The trial has dosed its first patient in cohort 6 at 3.0 x 106 cells per kilogram, a 50% increase from the previous maximum dose, after no dose-limiting toxicities were observed. The company aims to complete patient enrollment in cohorts 6 and 7 by mid-2023. CEO Pierluigi Paracchi noted the significance of this step in confirming Temferon's mechanism and therapeutic potential.
Genenta Science (NASDAQ: GNTA) announced preliminary findings from its Phase 1/2a study of Temferon™ for glioblastoma multiforme (uMGMT-GBM). The results show Temferon's potential to modulate the tumor microenvironment, with a positive safety profile. Fifteen patients received the treatment, showing successful engraftment and no drug-limiting toxicities. Preliminary signals of biological activity were observed, including gene-marked cells in tumors of patients who underwent surgery. The findings will be presented at the ASGCT meeting on May 19, 2022.
Genenta Science (NASDAQ: GNTA) has announced the appointment of Mark A. Sirgo, PharmD, as the new Chair, succeeding Stephen Squinto, who is stepping down to pursue a new opportunity. Dr. Sirgo brings over 35 years of pharmaceutical experience, including a successful tenure as CEO of Biodelivery Sciences, where he raised over $600 million and increased the market cap from $10 million to nearly $1 billion. His appointment is subject to shareholder approval at the next AGM. The company is advancing its proprietary stem cell gene therapy Temferon™ in clinical trials for solid tumor cancers.
Genenta Science (NASDAQ: GNTA) announced a webinar titled "Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors," scheduled for April 28, 2022, at 8:00 AM EDT. Esteemed speakers include neuro-oncologist David Reardon from Harvard Medical School and gene therapy pioneer Luigi Naldini. The discussion will focus on Genenta's Temferon™, an innovative gene therapy aimed at treating glioblastoma and solid tumors. A Q&A session will follow. Registration is available via Genenta's news release.
Genenta Science (NASDAQ: GNTA) announced that it will present clinical data at the 2022 American Association for Cancer Research (AACR) meeting regarding its Temferon™ treatment for glioblastoma multiforme patients with unmethylated MGMT gene promoter (uMGMT-GBM). Data from 15 patients suggest successful engraftment of gene-modified cells and maintained levels for up to 18 months post-treatment.
Safety continues to be a focus, with manageable adverse events linked primarily to chemotherapy. The presentation is scheduled for April 8-13, 2022, in New Orleans.
Genenta Science (NASDAQ: GNTA) announced its participation in several upcoming investor conferences. The events include the 34th Annual ROTH Conference on March 13-15, Maxim Group LLC 2022 Virtual Growth Conference on March 28, and the HC Wainwright Gene Therapy and Gene Editing Conference on March 30. Management, including CEO Pierluigi Paracchi and CMO Carlo Russo, will engage in fireside chats and one-on-one meetings with investors. Genenta is focused on developing Temferon™, a novel gene therapy targeting solid tumors.
FAQ
What is the current stock price of Genenta Science S.p.A. American Depositary Shares (GNTA)?
What is the market cap of Genenta Science S.p.A. American Depositary Shares (GNTA)?
What is Genenta Science's main area of research?
What are some of the key products developed by Genenta Science?
How does Genenta's gene therapy work?
What recent advancements has Genenta Science made?
Where is Genenta Science headquartered?
What is Temferon?
What are TIE2-expressing monocytes (TEMs)?
How does Genenta ensure the safety of their gene therapies?
What is the significance of the Phase 1/2 clinical trials?
Who can I contact for more information about Genenta Science?
